Iridex Corp

Day range

$0.73 – $0.76

Open

$0.73

Prev close

$0.75

Volume

7.48K

Market cap

$13.1M

Shares out

17.56M

P/E

—

P/S

0.26

P/B

3.62

P/FCF

—

ROE

-97.5%

ROA

-13.0%

Debt/Equity

1.04

Div yield

0.00%

As of Oct 23, 2026

• Listing deficiency noticeSep 2, 2026

  On August 27, 2026, IRIDEX Corporation (the "Company") received a notification of non-compliance (the "Notice") from Nasdaq's Listing Qualifications Department ... notifying the Company that, for the last 30 consecutive business days, the minimum bid price of the Company's common stock had been below the $1.00 per share minimum requirement for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).

• Annual meeting resultsJul 16, 2026

  Based on the votes set forth above, each director nominee was duly elected to serve until the 2027 Annual Meeting of Stockholders or until his or her respective successor is duly elected and qualified or until his or her earlier death, resignation or removal. The director nominees elected were Nick Chen, Beverly A. Huss, Patrick Mercer, William Moore, and Scott Shuda.

• Shareholder meeting noticeJun 18, 2026

  The Annual Meeting will reconvene at 8:00 a.m., Pacific Time, on Friday, July 10, 2026. The Annual Meeting will still be held in person at the Company's principal executive offices located at 1212 Terra Bella Avenue, Mountain View, California 94043. The record date for stockholders entitled to vote at the Annual Meeting remains April 17, 2026.

• Lease agreementMar 13, 2026

  On March 9, 2026, IRIDEX Corporation (the "Company") and SFIII Hellyer, LLC and SFIII FOS Hellyer Holding, LLC (the "Landlord") entered into a triple net lease (the "Lease") pursuant to which the Company will lease office space located at 5215 Hellyer Avenue in San Jose, California (the "Leased Space") as the Company's new corporate headquarters. The Leased Space consists of approximately 30,784 square feet. The Lease term is anticipated to commence on July 1, 2026 or such earlier date as the Company begins occupancy of the Leased Space for its business operations. The term of the Lease is 90 months from the commencement date.

• Preliminary resultsJan 12, 2026

  IRIDEX Corporation (the "Company") announced its preliminary, unaudited operational and financial results for its fourth fiscal quarter and full fiscal year ended January 3, 2026.

Days to cover

3.5

Short interest

131.66K

Avg volume

37.76K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Iridex Announces the Publication of Two-Year Independent Study Supporting Benefits of MicroPulse® Technology for Early to Advanced Glaucoma
  positiveGlobeNewswire Inc.· Oct 12, 2026
• Iridex Announces Plans to Relocate Headquarters
  positiveGlobeNewswire Inc.· Feb 2, 2026
• Iridex Announces the Publication of an Independent Study Demonstrating Safe and Effective Retreatment with Transscleral Laser Treatment Using MicroPulse® Technology in Glaucoma Management
  positiveGlobeNewswire Inc.· Dec 11, 2025
• Iridex Reports 7 Percent Q2 Revenue Gain
  neutralThe Motley Fool· Aug 12, 2025
• Iridex Comments on Recent Stock Price Volatility
  neutralGlobeNewswire Inc.· Mar 14, 2025